B. Riley Securities Upgrades Bicycle Therapeutics to Buy, Announces $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel has upgraded Bicycle Therapeutics (NASDAQ:BCYC) from Neutral to Buy and set a price target of $33.
September 12, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bicycle Therapeutics has been upgraded from Neutral to Buy by B. Riley Securities, with a new price target of $33.
The upgrade from Neutral to Buy indicates a positive outlook for Bicycle Therapeutics. The new price target of $33 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100